Vedanta Biosciences, a Cambridge, Mass-based clinical stage company which is developing therapies for the immune-mediated disease based on the rationally defined consortia of the human microbiome derived bacteria has now secured $27 Million in the funding round of Series C.
The backers include the Bill & Melinda Gates Foundation, Bristol Myers Squibb, Rock Springs Capital, Invesco Asset Management, PureTech Health, and Seventure Partners.
The company as of now has a plans to use the funds to advance its pipeline of the microbiome derived product candidates, which even includes a Phase ½ study of the VE416 in the food allergy, a phase 1b/2 study of VE800 and Opdivo in advanced or metastatic cancers and recently initiated Phase 2 study of VE303 in the recurrent Clostridium difficile infection.
The startup which is led by the Bernat Olle. Vedanta Biosciences develops a new category of therapies for the immune-mediated diseases based on the rationally defined consortia of the human microbiome derived bacteria. The company as of now is a leader in the microbiome field with the capabilities and deep expertise to develop, discover, and manufacture live bacteria drugs.
These also include an extensive collection of the human microbiome associated bacteria strains, a suite of proprietary assays to select pharmacologically potent strains, huge proprietary datasets from the human interventional studies, and facilities for the cGMP compliant manufacturing of the rationally defined bacterial consortia in the form of powder.
It also works in collaboration with its specific co-founders and has led to the identification of the human commensal bacteria that induce a range of immune responses, that even includes induction of the regulatory T cells, CD8+ T cells and the Th17 cells, and others.
“We are now so much excited to have the support of our new and existing investors as we continue to build on our leadership position in the entire field of the microbiome,” said Bernat Olle, said in an interview. “We have demonstrated some of the more rationally-defined bacterial consortia as a new drug modality which can be safe, well-tolerated, and have favorable pharmacokinetics and pharmacodynamics in humans. ”
You may also like to read: